#Novamind news update

(“ Hinterland“) and Novamind Ventures Inc. (“ Novamind” or the “ Company“), a leading mental health and wellness company specialized in psychedelic-assisted psychotherapy, today announced that Novamind has closed an oversubscribed private placement of subscription receipts (the “ Financing“), raising aggregate gross proceeds of CAD$10.0 million, twice the original CAD$5.0 million target. TORONTO, ON / ACCESSWIRE / Novem/ Hinterland Metals Inc. Any failure to comply with this restriction may constitute a violation of U.S. newswire services or for dissemination in the United States.

#Novamind news update

The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.Anticipates trading on CSE under ticker symbol “NM” upon completion of RTO. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information.

Important factors that could cause actual results to differ materially from the Company's expectations including the risks detailed from time to time in the Company's public disclosure. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. This news release contains forward-looking statements. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. A short Q&A session will follow.įor more information about the event and to register for free, visit: About Novamind

Conforti will deliver a presentation to update investors on the Company's rapidly growing network of psychiatry clinics and clinical research sites focused on psychedelic medicine. Novamind's CEO and Director, Yaron Conforti, will join a panel of industry leaders for a discussion titled, ' Addressing Mental Health through Emerging Therapies' on Thursday, September 30 at 12:35 PM EST.įollowing the panel, from 1:15 PM to 1:30 PM EST, Mr. (CSE: NM) (OTCQB: NVMDF) (FSE: HN2) ('Novamind' or the 'Company'), a leading mental health company specialized in psychedelic medicine, will participate in the Benzinga Small Cap Healthcare Conference taking place virtually on September 29-30, 2021. Novamind to Present at Benzinga Healthcare Conference Novamind to be featured in panel discussion on the disruptive potential of psychedelic medicine in mental healthcare

Company Overview Our Team Our Commitment Success Stories Upcoming Conferences Careers.